Insights & Publications
Research Library
Explore in-depth articles, studies and analysis from our research team.
Ipamorelin Research: GH Secretagogue Mechanism & Evidence
Ipamorelin is a selective 5-amino acid GH secretagogue studied for its clean GH pulse profile. Full mechanism, selectivity data, and research overview for lab use.
TB-500 vs BPC-157: Mechanism & Research Comparison
TB500 and BPC-157 are the two most studied synthetic peptides in musculoskeletal research. Full mechanism comparison, key differences, and research overview.
Semaglutide (Ozempic) Research: GLP-1 Receptor Mechanism Explained
Semaglutide — the molecule behind Ozempic — is a GLP-1 receptor agonist studied across 10+ major clinical trials. Full mechanism, trial overview, and UK research status.
BPC-157 Mechanism & Research: 30 Years of Preclinical Evidence
BPC-157 is a 15-amino acid synthetic peptide with 100+ peer-reviewed publications across musculoskeletal, GI, and neurological research models. Full mechanism overview.
Wolverine Protocol: BPC-157 + TB-500 Mechanisms & Evidence
BPC-157 and TB-500, the Wolverine Protocol stack: distinct mechanisms, published preclinical evidence and why researchers study them together. Research only.
UK Peptide Research: A Beginner’s Complete Guide (2026)
New to peptide research in the UK? This complete guide covers what peptides are, the 4 main categories, how to read a COA, storage rules, and…
FOXO4-DRI: The Senolytic Peptide That Targets Zombie Cells
FOXO4-DRI (CAS 2460055-10-9) selectively eliminates senescent cells by disrupting the FOXO4-p53 interaction. Full UK research guide: mechanism, 5 published studies, storage, and legal status.
AOD-9604 Research Guide: HGH Fragment 176-191 Explained (2026)
AOD-9604 (CAS 221231-10-3) is a synthetic HGH fragment studied for lipolysis and fat metabolism. Complete research guide: mechanism, 6 human trials, storage, and UK legal status.
What Is Retatrutide? Triple Agonist GLP-1 Compound Explained
Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 TRIUMPH-4 data: 28.7% weight loss at 68 weeks. Full 2026 guide - mechanism, trials, UK status.